


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL:

USAN	ALISKIREN FUMARATE
PRONUNCIATION	al is kye' ren fue' mar ate
THERAPEUTIC CLAIM	treatment of essential hypertension (renin inhibitor)

CHEMICAL NAMES

- 1) Benzeneoctanamide, δ -amino-*N*-(3-amino-2,2-dimethyl-3-oxopropyl)- γ -hydroxy-4-methoxy-3-(3-methoxypropoxy)- α,ζ -bis(1-methylethyl)-, ($\alpha S, \gamma S, \delta S, \zeta S$)-, (*2E*)-2-butenedioate (2:1) (salt)
- 2) Bis(*2S,4S,5S,7S*)-5-amino-*N*-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(1-methylethyl)nonanamide] (*2E*)-but-2-enedioate

STRUCTURAL FORMULA



MOLECULAR FORMULA	$(C_{30}H_{53}N_3O_6)_2 \cdot C_4H_4O_4$
MOLECULAR WEIGHT	1219.6
TRADEMARK	Unknown as yet
MANUFACTURER	Novartis Pharma AG (Switzerland)
CODE DESIGNATION	SPP100
CAS REGISTRY NUMBER	173334-58-2

- NOTE: 1) This Statement of Adoption supersedes the Statement for aliskiren hemifumarate, adopted as USAN on March 30, 2005.
 2) The USAN aliskiren hemifumarate is hereby rescinded.